WO2004080586A1 - 微粒子、その製造方法及び製造装置、並びに注射剤及びその製造方法 - Google Patents
微粒子、その製造方法及び製造装置、並びに注射剤及びその製造方法 Download PDFInfo
- Publication number
- WO2004080586A1 WO2004080586A1 PCT/JP2004/002909 JP2004002909W WO2004080586A1 WO 2004080586 A1 WO2004080586 A1 WO 2004080586A1 JP 2004002909 W JP2004002909 W JP 2004002909W WO 2004080586 A1 WO2004080586 A1 WO 2004080586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organic compound
- liquid
- wavelength
- treated
- laser light
- Prior art date
Links
- 239000010419 fine particle Substances 0.000 title claims abstract description 226
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 145
- 238000002347 injection Methods 0.000 title claims abstract description 46
- 239000007924 injection Substances 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 46
- 239000003795 chemical substances by application Substances 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 3
- 238000010521 absorption reaction Methods 0.000 claims abstract description 258
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 209
- 239000007788 liquid Substances 0.000 claims abstract description 198
- 239000002904 solvent Substances 0.000 claims abstract description 92
- 230000001678 irradiating effect Effects 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims description 193
- 229940079593 drug Drugs 0.000 claims description 191
- 238000002835 absorbance Methods 0.000 claims description 76
- 239000004094 surface-active agent Substances 0.000 claims description 35
- 239000003381 stabilizer Substances 0.000 claims description 21
- 238000000926 separation method Methods 0.000 claims description 19
- 238000012544 monitoring process Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 6
- 239000007951 isotonicity adjuster Substances 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000006552 photochemical reaction Methods 0.000 abstract description 47
- 238000000889 atomisation Methods 0.000 abstract description 19
- 239000012530 fluid Substances 0.000 abstract 4
- 238000001179 sorption measurement Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 103
- 239000000126 substance Substances 0.000 description 53
- 239000000243 solution Substances 0.000 description 30
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 28
- 229960005465 clobetasone butyrate Drugs 0.000 description 28
- 239000002245 particle Substances 0.000 description 24
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 23
- 229960000623 carbamazepine Drugs 0.000 description 23
- 230000008859 change Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 230000031700 light absorption Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000012545 processing Methods 0.000 description 18
- 239000000725 suspension Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 14
- 239000010453 quartz Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 12
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000011859 microparticle Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- -1 aromatic polycyclic compound Chemical class 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007721 medicinal effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 238000000149 argon plasma sintering Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000012929 tonicity agent Substances 0.000 description 4
- 230000035502 ADME Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005979 thermal decomposition reaction Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005274 electronic transitions Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- FBRAWBYQGRLCEK-AVVSTMBFSA-N Clobetasone butyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CCC)[C@@]1(C)CC2=O FBRAWBYQGRLCEK-AVVSTMBFSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
- B01J19/12—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
- B01J19/121—Coherent waves, e.g. laser beams
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
- B01J2219/0873—Materials to be treated
- B01J2219/0881—Two or more materials
- B01J2219/089—Liquid-solid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Electromagnetism (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/547,549 US20060257489A1 (en) | 2003-03-07 | 2004-03-05 | Fine particles, method and device for preparation thereof, and agent for parenteral injection and method for production thereof |
EP04717864A EP1602404B1 (en) | 2003-03-07 | 2004-03-05 | Medicament in fine particle form, method and device for preparation thereof, and agent for parenteral injection and method for production thereof |
DE602004019055T DE602004019055D1 (de) | 2003-03-07 | 2004-03-05 | Medikament in form feiner teilchen, verfahren und vorrichtung zu seiner herstellung und mittel zur parenteralen injektion und herstellungsverfahren dafür |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003062452A JP4344153B2 (ja) | 2003-03-07 | 2003-03-07 | 微粒子の製造方法及び製造装置、並びに注射剤の製造方法 |
JP2003-062452 | 2003-03-07 | ||
JP2003171051A JP4398182B2 (ja) | 2003-06-16 | 2003-06-16 | 微粒子の製造方法、並びに注射剤の製造方法 |
JP2003-171051 | 2003-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004080586A1 true WO2004080586A1 (ja) | 2004-09-23 |
Family
ID=32992929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/002909 WO2004080586A1 (ja) | 2003-03-07 | 2004-03-05 | 微粒子、その製造方法及び製造装置、並びに注射剤及びその製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060257489A1 (ja) |
EP (1) | EP1602404B1 (ja) |
DE (1) | DE602004019055D1 (ja) |
WO (1) | WO2004080586A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007132852A1 (ja) * | 2006-05-15 | 2007-11-22 | Ebara Corporation | 難水溶性医薬 |
US7597278B2 (en) * | 2006-05-15 | 2009-10-06 | Osaka University | Method of producing medicinal nanoparticle suspension |
US7597277B2 (en) | 2003-12-18 | 2009-10-06 | Hamamatsu Photonics K.K. | Microparticles, microparticle production method, and microparticle production apparatus |
US7838843B2 (en) | 2005-03-14 | 2010-11-23 | Hamamatsu Photonics K.K. | Carbon nano tube processing method, processing apparatus, and carbon nano tube dispersion liquid, carbon nano tube powder |
US7938344B2 (en) | 2003-11-20 | 2011-05-10 | Hamamatsu Photonics K.K. | Microparticles, microparticle production method, and microparticle production apparatus |
CN102429907A (zh) * | 2006-06-22 | 2012-05-02 | 日本化学医药株式会社 | 抗癌药耐性克服剂 |
JP2013501051A (ja) * | 2009-08-06 | 2013-01-10 | 株式会社エービーサイズ | ナノ粒子の溶液およびナノ粒子の懸濁物の両者を有する局所用薬学的調製物ならびに該調製物をもって急性疼痛および慢性疼痛を処置する方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007301534A (ja) * | 2006-05-15 | 2007-11-22 | Ebara Corp | 微細化装置 |
US8445019B2 (en) * | 2007-09-26 | 2013-05-21 | Hamamatsu Photonics K.K. | Microparticle dispersion liquid manufacturing method and microparticle dispersion liquid manufacturing apparatus |
US9168504B2 (en) * | 2010-03-11 | 2015-10-27 | Hamamatsu Photonics K.K. | Fine-particle dispersion liquid manufacturing method and fine-particle dispersion liquid manufacturing apparatus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0463203A (ja) * | 1990-06-29 | 1992-02-28 | Agency Of Ind Science & Technol | 超微粒子懸濁液の作成方法 |
JP2001113159A (ja) * | 1999-10-14 | 2001-04-24 | Dainippon Ink & Chem Inc | 有機化合物の微粒子の製造方法 |
JP2003025299A (ja) * | 2001-07-11 | 2003-01-29 | Hitachi Software Eng Co Ltd | 半導体ナノ粒子及びその製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3600291A (en) * | 1969-01-28 | 1971-08-17 | Atomic Energy Commission | Method of producing dense carbon from anthracene |
US4230546A (en) * | 1977-08-19 | 1980-10-28 | Research Foundation Of The City University Of New York | Method of molecular specie alteration by nonresonant laser induced dielectric breakdown |
US5354563A (en) * | 1985-07-15 | 1994-10-11 | Research Development Corp. Of Japan | Water dispersion containing ultrafine particles of organic compounds |
DE3623376A1 (de) * | 1986-07-11 | 1988-01-21 | Behringwerke Ag | Pharmazeutische formulierung und verfahren zu deren herstellung |
-
2004
- 2004-03-05 WO PCT/JP2004/002909 patent/WO2004080586A1/ja active Application Filing
- 2004-03-05 US US10/547,549 patent/US20060257489A1/en not_active Abandoned
- 2004-03-05 EP EP04717864A patent/EP1602404B1/en not_active Expired - Fee Related
- 2004-03-05 DE DE602004019055T patent/DE602004019055D1/de not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0463203A (ja) * | 1990-06-29 | 1992-02-28 | Agency Of Ind Science & Technol | 超微粒子懸濁液の作成方法 |
JP2001113159A (ja) * | 1999-10-14 | 2001-04-24 | Dainippon Ink & Chem Inc | 有機化合物の微粒子の製造方法 |
JP2003025299A (ja) * | 2001-07-11 | 2003-01-29 | Hitachi Software Eng Co Ltd | 半導体ナノ粒子及びその製造方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1602404A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7938344B2 (en) | 2003-11-20 | 2011-05-10 | Hamamatsu Photonics K.K. | Microparticles, microparticle production method, and microparticle production apparatus |
US7597277B2 (en) | 2003-12-18 | 2009-10-06 | Hamamatsu Photonics K.K. | Microparticles, microparticle production method, and microparticle production apparatus |
US7838843B2 (en) | 2005-03-14 | 2010-11-23 | Hamamatsu Photonics K.K. | Carbon nano tube processing method, processing apparatus, and carbon nano tube dispersion liquid, carbon nano tube powder |
WO2007132852A1 (ja) * | 2006-05-15 | 2007-11-22 | Ebara Corporation | 難水溶性医薬 |
US7597278B2 (en) * | 2006-05-15 | 2009-10-06 | Osaka University | Method of producing medicinal nanoparticle suspension |
US8399024B2 (en) | 2006-05-15 | 2013-03-19 | Ebara Corporation | Water-insoluble medicine |
CN102429907A (zh) * | 2006-06-22 | 2012-05-02 | 日本化学医药株式会社 | 抗癌药耐性克服剂 |
JP2013501051A (ja) * | 2009-08-06 | 2013-01-10 | 株式会社エービーサイズ | ナノ粒子の溶液およびナノ粒子の懸濁物の両者を有する局所用薬学的調製物ならびに該調製物をもって急性疼痛および慢性疼痛を処置する方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1602404A1 (en) | 2005-12-07 |
DE602004019055D1 (de) | 2009-03-05 |
EP1602404A4 (en) | 2006-11-15 |
EP1602404B1 (en) | 2009-01-14 |
US20060257489A1 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wei et al. | Fabrication, characterization and in vitro digestion of food grade complex nanoparticles for co-delivery of resveratrol and coenzyme Q10 | |
JP4482322B2 (ja) | 微粒子の製造方法、及び製造装置 | |
JP4142675B2 (ja) | フラーレン分散液の製造方法 | |
Mauludin et al. | Kinetic solubility and dissolution velocity of rutin nanocrystals | |
WO2004080586A1 (ja) | 微粒子、その製造方法及び製造装置、並びに注射剤及びその製造方法 | |
Razmimanesh et al. | An investigation into Sunitinib malate nanoparticle production by US-RESOLV method: Effect of type of polymer on dissolution rate and particle size distribution | |
JP4344153B2 (ja) | 微粒子の製造方法及び製造装置、並びに注射剤の製造方法 | |
Gupta et al. | Formulation and characterization of curcumin loaded polymeric micelles produced via continuous processing | |
Liu et al. | Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology | |
JP2007045674A5 (ja) | フラーレン分散液の製造方法 | |
Corti et al. | Physical–chemical characterization of binary systems of metformin hydrochloride with triacetyl-β-cyclodextrin | |
Feng et al. | Fabrication and characterization of water-soluble phytosterol ester nanodispersion by emulsification-evaporation combined ultrasonic method | |
JPH04264029A (ja) | テポキサリンの眼科用水性微細乳濁液 | |
Lee et al. | Polymer concentration maximizes encapsulation efficiency in electrohydrodynamic mixing nanoprecipitation | |
CN108635588B (zh) | 药物小分子修饰的贵金属纳米粒子及其制备方法和应用 | |
JP4398182B2 (ja) | 微粒子の製造方法、並びに注射剤の製造方法 | |
Mohammadi et al. | Determination of amiodarone hydrochloride solubility in pure and ethanol-modified subcritical water: Experimental data and modeling | |
WO2005092489A1 (ja) | 微粒子化条件の決定方法、決定装置、及び微粒子の製造方法、製造装置 | |
Yang et al. | Phytosterols photooxidation in O/W emulsion: Influence of emulsifier composition and interfacial properties | |
Boni et al. | Laser beams interaction with liquids in optofluidic experiments | |
Chen et al. | Antioxidant activity of vitamin E enhanced by cyclodextrin inclusion complex | |
Štukelj et al. | SYNTHESIS OF STABLE CANNABIDIOL (CBD) NANOPARTICLES IN SUSPENSION. | |
Bettini et al. | Thermal and morphological characterization of micronized acetylsalicylic acid powders prepared by rapid expansion of a supercritical solution | |
JP4408245B2 (ja) | 微粒子の製造方法、及び製造装置 | |
JP2005125204A (ja) | 微粒子、微粒子の製造方法、及び製造装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20048041491 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004717864 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004717864 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006257489 Country of ref document: US Ref document number: 10547549 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10547549 Country of ref document: US |